Journal ArticleDOI
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Bruce E. Hillner,James N. Ingle,Rowan T. Chlebowski,Julie Gralow,Gary C. Yee,Nora A. Janjan,Jane A. Cauley,Brent A. Blumenstein,Kathy S. Albain,Allan Lipton,Susan Brown +10 more
TLDR
Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases and an algorithm for patient management to maintain bone health is recommended.Abstract:
Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less t...read more
Citations
More filters
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
Salvatore L. Ruggiero,Thomas B. Dodson,John Fantasia,Reginald Goodday,Tara Aghaloo,Bhoomi Mehrotra,Felice O'Ryan +6 more
TL;DR: The American Association of Oral and Maxillofacial Surgeons (AAOMS) developed guidelines for medication-related osteonecrosis of the jaw (MRONJ) in 2007 and 2009 as mentioned in this paper.
Journal ArticleDOI
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
TL;DR: Improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update
Salvatore L. Ruggiero,Thomas B. Dodson,Leon A. Assael,Regina Landesberg,Robert E. Marx,Bhoomi Mehrotra +5 more
TL;DR: This update contains revisions to the diagnosis and staging and management strategies and highlights the status of basic science research.
Journal ArticleDOI
Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research
Sundeep Khosla,David B. Burr,Jane A. Cauley,David W. Dempster,Peter R. Ebeling,Dieter Felsenberg,Robert F. Gagel,Vincente Gilsanz,Theresa A. Guise,Sreenivas Koka,Laurie K. McCauley,Joan McGowan,Marc D. McKee,Suresh Mohla,David G. Pendrys,Lawrence G. Raisz,Salvatore L. Ruggiero,David Shafer,Lillian Shum,Stuart L. Silverman,Catherine Van Poznak,Nelson B. Watts,Sook-Bin Woo,Elizabeth Shane +23 more
TL;DR: This report summarizes the findings and recommendations of the task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder.
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
TL;DR: Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
Journal ArticleDOI
Cox's Regression Model for Counting Processes: A Large Sample Study
TL;DR: In this article, the Cox regression model for censored survival data is extended to a model where covariate processes have a proportional effect on the intensity process of a multivariate counting process, allowing for complicated censoring patterns and time dependent covariates.
Journal ArticleDOI
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger,Dennis M. Black,Bruce H. Mitlak,Ronald Keith Knickerbocker,Thomas Nickelsen,Harry K. Genant,Claus Christiansen,Pierre D. Delmas,Jose R. Zanchetta,J. A. Stakkestad,Claus C. Glüer,Kathryn A. Krueger,Fredric J. Cohen,Stephen Eckert,Kristine E. Ensrud,Louis V. Avioli,Paul Lips,Steven R. Cummings +17 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) study as mentioned in this paper evaluated the effect of raloxion hydrochloride therapy on risk of vertebral and non-vertebral fractures.
Journal ArticleDOI
Diagnosis of osteoporosis and assessment of fracture risk
TL;DR: Although hip fracture prediction with BMD alone is at least as good as blood pressure readings to predict stroke, the predictive value of BMD can be enhanced by use of other factors, such as biochemical indices of bone resorption and clinical risk factors.
Related Papers (5)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C. Coombes,Emma Hall,Lorna Gibson,Robert Paridaens,Jacek Jassem,Thierry Delozier,Stephen E. Jones,Isabel Alvarez,Gianfilippo Bertelli,Olaf Ortmann,Alan S. Coates,Emilio Bajetta,D. Dodwell,Robert E. Coleman,Lesley Fallowfield,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,Alan L Stewart,N Stuart,Claire Snowdon,M. Carpentieri,Giorgio Massimini,Judith M Bliss +24 more
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,David Cameron,Michael Palmer,Joseph L. Pater +17 more